Female Infertility Pipeline and Clinical Trials Assessment (2023) | Companies- Oxolife, ObsEva, Shandong TheraWisdom Biopharma Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Spruce Biosciences, EffRx, Ogeda, KinDex Pharmaceuticals, Forendo Pharma, and oth

(Albany, 07 June, 2023), DelveInsight's "Female Infertility Pipeline Insight 2023" report offers extensive knowledge on more than 12+ companies and 12+ pipeline drugs within the landscape of Female Infertility research. The Female Infertility Pipeline report provides detailed profiles of the pipeline drugs, encompassing both Female Infertility clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

The pipeline analysis report for emerging drugs in Female Infertility offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Female Infertility pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, clinical trial studies conducted for Female Infertility, any obtained NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.

To explore more information on the latest breakthroughs in the Female Infertility Pipeline treatment landscape of the report, click here @ Female Infertility Pipeline Outlook- https://www.delveinsight.com/sample-request/female-infertility-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Female Infertility Pipeline Report
• DelveInsight's Female Infertility Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
• The leading Female Infertility Companies are working in the market include Oxolife, ObsEva, Shandong TheraWisdom Biopharma Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Spruce Biosciences, EffRx, Ogeda, KinDex Pharmaceuticals, Forendo Pharma, and others
• Promising Female Infertility Pipeline Therapies in the various stages of development include Dydrogesterone 30 mg, Micronized Progesterone 600 mg, Intravaginal progesterone gel 90 mg, Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen, Follitropin alpha, Menotropin, Follitropin delta, Epifasi: Human chorionic gonadotrophin, Pregnyl: Human chorionic gonadotrophin, Menopur® Inj., Follitropin alfa (Gonal-f), and others
• OXO-001, a first-in class oral drug that acts directly on the endometrium to enhance and improve the embryo implantation process, which is a breakthrough innovation in reproductive medicine. After having demonstrated its efficacy in preclinical trials and its safety in humans, Oxolife has already initiated a Phase II international clinical trial (OXOART2) with the drug. The main objective of this ongoing clinical trial is to demonstrate the efficacy of OXO-001 in increasing the pregnancy rate of infertile women. Another research with OXO-001 is an innovative approach to PCOS infertility treatment. Previous preclinical studies performed have shown OXO-001 is capable of recovering ovulation and fertility in an animal model with PCOS characteristics, and we are currently in late stages of the pre-clinical development for this condition.
• ObsEva is currently advancing nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful pregnancy and live-birth among patients undergoing embryo transfer following ART. The Phase 2 dose-ranging IMPLANT 1 clinical trial (n=247) showed that a single oral 900 mg dose of nolasiban about 4 h before fresh, day 3, single or double embryo transfer had the highest increase in on-going pregnancy and live birth rates compared to lower doses of 100 and 300 mg and placebo.

Female Infertility Overview
Female infertility refers to the inability to conceive even after actively attempting for a minimum of one year (or six months for women over the age of 35). If a woman experiences recurrent miscarriages, it is also categorized as infertility. Factors such as age, physical conditions, hormonal imbalances, and lifestyle or environmental influences can contribute to female infertility. The majority of cases of infertility in women arise from difficulties in egg production.

For further information, refer to the detailed Female Infertility Unmet Needs, Female Infertility Market Drivers, and Female Infertility Market Barriers, click here for Female Infertility Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/female-infertility-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Female Infertility Emerging Drugs Profile
• OXO-001: Oxolife
• Nolasiban: ObsEva

Female Infertility Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the therapies for Female Infertility. The companies which have their Female Infertility drug candidates in the most advanced stage, i.e. phase II include, Oxolife.

Request a sample and discover the recent advances in Female Infertility Ongoing Clinical Trial Analysis and Medications, click here @ Female Infertility Treatment Landscape- https://www.delveinsight.com/sample-request/female-infertility-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Female Infertility Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Female Infertility Therapeutics Market include-
Oxolife, ObsEva, Shandong TheraWisdom Biopharma Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Spruce Biosciences, EffRx, Ogeda, KinDex Pharmaceuticals, Forendo Pharma, and others

Dive deep into rich insights for drugs for Female Infertility Pipeline, click here @ Female Infertility Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/female-infertility-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Female Infertility Pipeline Report
• Coverage- Global
• Female Infertility Companies- Oxolife, ObsEva, Shandong TheraWisdom Biopharma Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Spruce Biosciences, EffRx, Ogeda, KinDex Pharmaceuticals, Forendo Pharma, and others
• Female Infertility Pipeline Therapies- Dydrogesterone 30 mg, Micronized Progesterone 600 mg, Intravaginal progesterone gel 90 mg, Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen, Follitropin alpha, Menotropin, Follitropin delta, Epifasi: Human chorionic gonadotrophin, Pregnyl: Human chorionic gonadotrophin, Menopur® Inj., Follitropin alfa (Gonal-f), and others
• Female Infertility Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Female Infertility Mergers and acquisitions, Female Infertility Licensing Activities @ Female Infertility Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/female-infertility-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Female Infertility: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Female Infertility - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. OXO-001: Oxolife
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. KDT-501: KinDex Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Female Infertility Key Companies
21. Female Infertility Key Products
22. Female Infertility- Unmet Needs
23. Female Infertility- Market Drivers and Barriers
24. Female Infertility- Future Perspectives and Conclusion
25. Female Infertility Analyst Views
26. Female Infertility Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.